NeuroOne Medical Technologies Corporation has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The medical technology company, which focuses on developing solutions for neurological disorders, now has until May 4, 2026, to maintain a closing bid price of at least $1.00 per share for its common stock. The extension provides NeuroOne with additional time to address the compliance issue that began when the company received notice from Nasdaq about failing to meet the minimum bid price requirement for 30 consecutive business days.
The original 180-day compliance period was set to expire on November 3, 2025, but the company had not yet regained compliance by that deadline. According to the company's announcement, the extension has no immediate effect on the continued listing status of NeuroOne's common stock, which remains fully effective on the Nasdaq Capital Market. The company has indicated its intent to cure the deficiency within the extended timeframe and will continue monitoring its stock's closing bid price. The implications of this extension are significant for NeuroOne's future on the public markets.
If the company fails to regain compliance within the new deadline, Nasdaq will issue a delisting notification, at which point NeuroOne could appeal the determination to a Nasdaq Hearing Panel. However, the company acknowledges there is no assurance that such an appeal would be successful if needed. NeuroOne specializes in developing minimally invasive and high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation for patients suffering from various neurological conditions. The company's technology targets disorders including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain resulting from failed back surgeries.
Additional information about the company's work is available at https://nmtc1.com. The minimum bid price requirement is one of several continued listing standards companies must maintain on Nasdaq. For NeuroOne, maintaining its Nasdaq listing is crucial for maintaining investor confidence and access to public capital markets as it continues developing neurological treatment technologies. The extended compliance period gives the company additional runway to implement strategies that could boost its stock price above the $1.00 threshold through operational improvements, corporate developments, or other market activities.
